TetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir AB
December 29, 2016 10:30 ET
|
TetraLogic Pharmaceuticals
PAOLI, Pa., Dec. 29, 2016 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) (“TetraLogic” or “Company”) and its wholly-owned subsidiary TetraLogic Research and Development...
TetraLogic Announces Agreements to Sell SMAC mimetic and HDAC inhibitor assets to Medivir and to Restructure its Convertible Senior Notes and Delisting of Common Stock
November 02, 2016 16:30 ET
|
TetraLogic Pharmaceuticals
PAOLI, Pa., Nov. 02, 2016 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) (“TetraLogic” or “Company”), a clinical-stage biopharmaceutical company focused on discovering and...
TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs
January 06, 2016 16:10 ET
|
TetraLogic Pharmaceuticals
Birinapant Shows No Activity in Randomized Phase 2 MDS Study SHAPE Shows Clinical Benefit in Randomized Phase 2 CTCL Study MALVERN, Pa., Jan. 06, 2016 (GLOBE NEWSWIRE) -- TetraLogic...
TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 57th Annual American Society of Hematology Annual Meeting
November 09, 2015 07:00 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 9, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts discussing clinical data on birinapant will be presented at the...
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
November 04, 2015 16:01 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 4, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata
November 02, 2015 07:00 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 2, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has an open U.S. Investigational New Drug application in support of a Phase...
TetraLogic Reports Second Quarter Financial Results and Provides Clinical Programs Update
August 05, 2015 16:01 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic to Present at the Jefferies 2015 Hepatitis B Summit
July 29, 2015 07:31 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., July 29, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) today announced that the Company will present at the Jefferies 2015 Hepatitis B Summit on Thursday,...
TetraLogic Provides Update on Hepatitis B Clinical Program
July 20, 2015 16:02 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., July 20, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) a clinical-stage biopharmaceutical company focuses on discovering and developing novel small...
TetraLogic Announces Update on MDS Clinical Program
June 30, 2015 16:01 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., June 30, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...